EFFECTIVE THERAPEUTIC MEASURES FOR REDUCING LIPOPROTEIN (A) IN PATIENTS WITH DYSLIPIDEMIA - LIPOPROTEIN (A) REDUCTION WITH SUSTAINED-RELEASE BEZAFIBRATE

被引：0
作者：
BIMMERMANN, A
BOERSCHMANN, C
SCHWARTZKOPFF, W
VONBAEYER, H
SCHLEICHER, J
机构：
来源：
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL | 1991年 / 49卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
The effect of sustained-release bezafibrate (400 mg in the evening) on blood lipids and lipoprotein (a) [Lp(a)] during 42 weeks of therapy was investigated in 70 patients with primary hyperlipoproteinemia (HLP) types IIa, IIb, and IV. Cholesterol decreased by 12% (HLP type IIa) and by 18% (HLP type IIb), respectively. In HLP type IV triglycerides fell by 27%. Lp(a) was reduced significantly (26%) by long-term therapy with sustained-release bezafibrate. Elevated Lp(a) concentrations above 30 mg/dl were reduced by 39%. The long-term effects of sustained-release bezafibrate on Lp(a) were best in patients with high baseline Lp(a) values and were independent of sex and HLP type.
引用
收藏
页码：635 / 643
页数：9
相关论文
共 27 条
123